Mechanism of Action Sitagliptin is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones.

A total of 1,091 patients with type 2 diabetes and HbA 1c levels of 7.5–11.0% were randomly assigned to receive combination therapy with daily sitagliptin (100 mg) and metformin (either 1,000 mg ...